Rare Variation in TET2 Is Associated with Clinically Relevant Prostate Carcinoma in African Americans.

Finding the missing heritability of complex diseases. Nature (2009) 67.95

Screening and prostate-cancer mortality in a randomized European study. N Engl J Med (2009) 35.94

Cancer statistics, 2016. CA Cancer J Clin (2016) 32.95

Mortality results from a randomized prostate-cancer screening trial. N Engl J Med (2009) 30.05

Genome-wide association study identifies a second prostate cancer susceptibility variant at 8q24. Nat Genet (2007) 19.18

Mutation in TET2 in myeloid cancers. N Engl J Med (2009) 16.07

Multiple regions within 8q24 independently affect risk for prostate cancer. Nat Genet (2007) 14.37

Genetic heterogeneity in human disease. Cell (2010) 10.67

Admixture mapping identifies 8q24 as a prostate cancer risk locus in African-American men. Proc Natl Acad Sci U S A (2006) 10.32

Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. J Natl Cancer Inst (2002) 9.45

Cancer risks in BRCA2 mutation carriers. J Natl Cancer Inst (1999) 8.15

Genetic risk prediction--are we there yet? N Engl J Med (2009) 7.30

Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context. J Natl Cancer Inst (2009) 6.96

Identification of seven new prostate cancer susceptibility loci through a genome-wide association study. Nat Genet (2009) 6.04

Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array. Nat Genet (2013) 5.58

Germline mutations in HOXB13 and prostate-cancer risk. N Engl J Med (2012) 5.49

Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene. Nat Genet (2010) 5.48

DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer. N Engl J Med (2015) 5.39

Integrative clinical genomics of advanced prostate cancer. Cell (2015) 5.29

Long-term follow-up of a large active surveillance cohort of patients with prostate cancer. J Clin Oncol (2014) 5.01

TET1, a member of a novel protein family, is fused to MLL in acute myeloid leukemia containing the t(10;11)(q22;q23). Leukemia (2003) 4.17

Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing. Proc Natl Acad Sci U S A (2011) 3.99

Prostate cancer progression and survival in BRCA2 mutation carriers. J Natl Cancer Inst (2007) 3.48

A meta-analysis of 87,040 individuals identifies 23 new susceptibility loci for prostate cancer. Nat Genet (2014) 2.72

Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer. J Clin Oncol (2013) 2.71

The heritability of prostate cancer in the Nordic Twin Study of Cancer. Cancer Epidemiol Biomarkers Prev (2014) 2.36

Familial concordance in cancer survival: a Swedish population-based study. Lancet Oncol (2007) 1.90

Black race is an adverse prognostic factor for prostate cancer recurrence following radical prostatectomy in an equal access health care setting. J Urol (1996) 1.77

Germline BRCA mutations denote a clinicopathologic subset of prostate cancer. Clin Cancer Res (2010) 1.68

Crystal structure of TET2-DNA complex: insight into TET-mediated 5mC oxidation. Cell (2013) 1.63

Prostate cancer in male BRCA1 and BRCA2 mutation carriers has a more aggressive phenotype. Br J Cancer (2008) 1.62

A population-based assessment of germline HOXB13 G84E mutation and prostate cancer risk. Eur Urol (2012) 1.55

Prostate cancer risk associated loci in African Americans. Cancer Epidemiol Biomarkers Prev (2009) 1.49

A meta-analysis of genome-wide association studies to identify prostate cancer susceptibility loci associated with aggressive and non-aggressive disease. Hum Mol Genet (2012) 1.47

Germline BRCA1 mutations increase prostate cancer risk. Br J Cancer (2012) 1.45

The genetic epidemiology of prostate cancer and its clinical implications. Nat Rev Urol (2013) 1.39

Early detection of prostate cancer. Hum Pathol (1992) 1.34

Removal of the financial barrier to health care: does it impact on prostate cancer at presentation and survival? A comparative study between black and white men in a Veterans Affairs system. Urology (1995) 1.28

Prostate cancer susceptibility variants confer increased risk of disease progression. Cancer Epidemiol Biomarkers Prev (2010) 1.06

Two susceptibility loci identified for prostate cancer aggressiveness. Nat Commun (2015) 1.06

Concordance of survival in family members with prostate cancer. J Clin Oncol (2008) 0.98

Associations of prostate cancer risk variants with disease aggressiveness: results of the NCI-SPORE Genetics Working Group analysis of 18,343 cases. Hum Genet (2015) 0.95

The contribution of rare variation to prostate cancer heritability. Nat Genet (2015) 0.94

Somatic alterations contributing to metastasis of a castration-resistant prostate cancer. Hum Mutat (2013) 0.92

Mutational landscape of candidate genes in familial prostate cancer. Prostate (2014) 0.85

Two percent of Finnish prostate cancer patients have a germ-line mutation in the hormone-binding domain of the androgen receptor gene. Cancer Res (2000) 0.84

One thousand genomes imputation in the National Cancer Institute Breast and Prostate Cancer Cohort Consortium aggressive prostate cancer genome-wide association study. Prostate (2012) 0.83

Concordance of tumor differentiation among brothers with prostate cancer. Eur Urol (2012) 0.80

Androgen receptor-regulated miRNA-193a-3p targets AJUBA to promote prostate cancer cell migration. Prostate (2017) 0.75